您所在的位置: 首页 --> 导师团队 --> 李惠平

导师基本信息

  • 姓名:李惠平
  • 性别:
  • 民族:汉族
  • 科室:乳腺肿瘤内科
  • 职称:主任医师 ,教授
  • 专业:肿瘤学 、肿瘤内科学
  • E-MAIL: huipingli2012@hotmail.com

学术论文 | 出版专著 | 奖励表彰 | 科研项目

(53) Huiping Li, Guohong Song, Qiaoxia Zhou, Ran Ran,et al, Ectivity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer, Breast Cancer Res Treatment, 2021 Aug, doi:10.1007/s10549-021-06345-x,Breast Cancer Research Treatment,2021 Aug, doi:10.1007/s10549-021-06345-x,prepringt

Huiping Li, 外院,Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer,Am J Cancer Res,2018;8(9):1873-1886

Hanfang Jiang and Huiping Li*,Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis,BMC Cancer . 2021 Feb 10;21(1):149,2021 Feb 10;21(1):149

Wen Lei 1, Huiping Li 1, Guohong Song 1, Ruyan Zhang 1, Ran Ran 1, Ying Yan 1, Lijun Di 1, Hanfang Jiang 1Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China,J Cancer,2020 Sep 23;11(22):6612-6622

3. 廖浩,李惠平等.Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer,Cancer Management and Research,2020 May 18;12

Xinyu Gui, Huiping Li, Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall A case report,Medicine,2018-97(48):e13410

Bin Shao, 外院,Huiping Li, Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer,International Journal of Clinical and Experimental Pathology,2018;11(2):650-663

Han Bai 1, Jianjun Yu 2, Shidong Jia 2, Xiaoran Liu 1, Xu Liang 1, Huiping Li 1Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing,Cancer Management and Research,2021 Apr 15;13:3303-3316.

Ruyan Zhang Xiaoran Liu Wenfa Huang Bin Shao Ying Yan Xu Liang Ran Ran Guohong Song Lijun Di Hanfang Jiang Huiping Li,Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study,Asia-Pac J Clin Oncol,2021;1–7.

外院,李惠平(并一)MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study,Therapeutic Advances in Medical Oncology,2020, Vol. 12: 1–14

Hao Liao1,, Wenfa Huang2?,, Yaxin Liu1,, Wendi Pei 3 and Huiping Li 1*Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis,Front Oncol,03 May 2021 | https://doi.org/10.3389/fonc.2021.608781

桂欣钰,*李惠平, CDK4/6抑制剂在激素受体阳性进展期乳腺癌中的治疗进展,中国肿瘤临床,2020年47卷6期 314-317页

廖浩,黄文发,李惠平. ESR1 Detection of Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects,Front Oncol,2020, 10: 587671

Bin Shao, 外院,Huiping Li, Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer,AMERICAN JOURNAL OF CANCER RESEARCH,2018;8(9):1837-1846

外院,Bin Shao, 外院,Huiping LI, Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles,Small Methods,2018;1800122

宋国红,肖宇,张如艳,冉然,王环,*李惠平,邸立军,严颖,姜晗昉,徐玲,真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性,北京大学学报,2020年52卷2期 254-260页

Wangshu Zheng, Wenzhe Li, Ping Li, Ling Zhu, Xiaoran Liu, Bin Shao, Huiping Li*, Chen Wang*, Yanlian Yang*. Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells,ACS APPLIED MATERIALS & INTERFACES,9(22):18423-18428

Mingxing Zhou, Hui Zheng, Zhaoba Wang, Ren Li, Xiaoran Liu, Weikai Zhang, Zihua Wang, Huiping Li*, Zewen Wei* and Zhiyuan Hu*. Precisely Enumerating Circulating Tumor Cells Utilizing a Multi-Functional Microfluidic Chip and Unique Image Interpretation Algorithm,Theranostics,7(19): 4710–4721

Liu XR, Shao B, Peng JX, Li HP, Yang YL, Kong WY, Song GH, Jiang HF, Liang X, Yan Y. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.,The Breast ,2017;32:119-125

Liu X, Li H, Shao B, Wu J, Kong W, Song G, Jiang H, Wang J, Wan F. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Med.,Cancer Medicine ,2017;6(3):547-554

李惠平# 冉然 李鹍 孔维垚 刘笑然 王晶 张如艳 邵彬 严颖 姜晗昉 刘雅昕 张嘉杨 176例HER2阳性乳腺癌首发转移部位的分析,癌症进展 ,2016;14(12):1167-1169

李惠平* # 刘笑然* 孔维垚 冉然 张如艳 张嘉杨 刘雅昕 韩祎帆 刘慧敏 金秋杰 125例三阴性复发转移乳腺癌首发转移模式的分析 ,癌症进展 ,2016;14(12):1184-1186

郭奕嫱,鞠庆梅,尤渺宁,Azlina Yusuf,辛小林,李惠平*,Soon Lean Keng,护理研究 ,31 (2) :145-147

冉然,李惠平*,严颖,刘笑然,张如艳,孔维垚. 小于35岁153例进展期乳腺癌患者的临床特征和预后,肿瘤 ,37(01):77-82

张如艳, 黄思宇, 李惠平*, 宋国红, 邸立军. 乳腺癌特殊部位转移68例临床特征及预后分析, 肿瘤 , 37 (2) :157-162

Xiao-ran L, Bin S, Jia-xi P, Huip-ing L*, Yan-lian Y*, Wei-yao K, Guo-hong S, Han-Fang J, Xu L, Ying Y. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.,CANCER MEDICINE ,31; 32: 119-125

Xiao-ran L, Hui-ping L*, Bin S, Jian-min W, Wei-yao K, Guo-hong S, Han-fang J, Jing W, Feng-ling W. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.,Cancer Medicine ,6; 3: 547-554

Huiping Li#, Jiang Liu#, Jianing Chen#, Huiyun Wang, Linbin Yang, Fei Chen, Siting Fan, Jing Wang, Bin Shao, Dong Yin, Musheng Zeng, Mengfeng Li, Jun Li, Fengxi Su, Qiang Liu, Herui Yao,Shicheng Su* & Erwei Song*, A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients,NATURE COMMUNICATIONS,(2018) 9:1614,

口服依托泊苷治疗难治性转移性乳腺癌的疗效及安全性,肿瘤防治研究 ,44 (5) :347-350

张霖惠,李惠平#,邵彬,宋国红,黄文发,冉然,刘笑然,孔维垚 依维莫司治疗激素受体阳性、HER2阴性进展期乳腺癌的疗效 及安全性研究,癌症进展 ,2019 年2 月第17 卷第3 期

王楠,李鹍,李惠平#,宋国红,邸立军,姜晗昉,刘笑然,孔维垚 铂类化疗药物对进展期三阴性乳腺癌的临床疗效及与BRCA 基因突变的关系,癌症进展 ,2019 年2 月第17 卷第4 期

Xiaoran Liu, Ranran, Huiping LI, Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer,Chinese Journal of Cancer Research,2018;30(3):1-12

黄文发(学)(第一作者)(是),冉然(中间作者)(是),邵彬(中间作者)(是),李惠平(通讯作者)(是),Prognostic and Clinicopathological Value of PD-L1 Expression in Primary Breast Cancer: A Meta-Analysis.,Breast Cancer Research and Treatment,Breast Cancer Research and Treatment,17-33

梁旭(第一作者)(是),李惠平(通讯作者)(是),外单位(外)(中间作者)(否),外单位(外)(并列通讯作者)(否),外单位(外)(中间作者)(否)An Update on Biomarkers of Potential Benefit With Bevacizumab for Breast Cancer Treatment: Do We Make Progress?,CHINESE JOURNAL OF CANCER RESEARCH,2019 Aug;31(4),586-600

中国进展期乳腺癌共识指南2020, 主编 , 中国协和医科大学出版社, 2021.5

中国女医师协会最美抗疫防控巾帼团队荣誉, 中国女医师协会最美抗疫防控巾帼团队荣誉, 第1完成人 , 中国女医师协会, 2020.9

李惠平获2019年度北京大学肿瘤医院优秀教师。, 李惠平获2019年度北京大学肿瘤医院优秀教师。, 第1完成人 , 北京大学肿瘤医院, 2019.10

第六届中国女医师协会五洲女子科技奖, 第六届中国女医师协会五洲女子科技奖临床科研创新奖, 第1完成人 , 中国女医师协会, 2019.10

PARP磷酸化水平与其在进展期乳腺癌治疗疗效的相关性研究, 课题负责人 , 2016.7.25~2017.8.25, 江苏恒瑞制药有限公司

国内多中心激素受体阳性、HER-2阴性复发转移性乳腺癌一线治疗患者数据库的建立, 课题负责人 , 2016.11.14~2018.1.14, 吴阶平医学基金会

难溶性药物口服纳米制剂的转运机制及临床转化研究, 子课题负责人 , 2015.11.23~2019.8.23, 973